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Background: The rates of target vessel revascularization (TVR) with sirolimus-eluting stents (SES) are low, but the incidence of late TVR is not well 
studied. In the bare metal stent era, TVR occurred predominantly in the first year post procedure. The objective of this study was to determine, using 
a prospective, real world SES registry, the temporal incidence of major adverse cardiovascular events (MACE) and clinically driven TVR according to 
on- or off-label indication.
Methods: The Scripps DES Real World registry is a single-center, prospective, all-comer registry of SES implantation with 2 year follow-up. Endpoints 
were assessed with respect to MI, TVR, and death. On-label indications were determined according to the SES instructions for use.
Results: The baseline characteristics of the patients are described in Table 1a.
SES were implanted in 150 and 709 patients in an on- and off-label fashion respectively. At one and two year follow-up, considerably higher rates 
of MACE and TVR were observed in the off-label groups (Table 1b). The on- and off-label groups had similar incremental rates of TVR between years 
1 and 2 (5.3% versus 5.8%, respectively). However, given the low rate of TVR during the first year, the majority of TVR in the on-label group occurred 
during the 2nd year of follow-up.
Conclusions: Off-label use of SES results in greater rates of MACE, largely driven by TVR. TVR after one year is relatively more important for patients 
treated for on-label indications, and is more clinically relevant. 
